Penumbra, Inc.
PENHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Penumbra, Inc. focuses on Medical Devices services and products. Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The $12.78B market capitalization puts PEN squarely in large-cap range for its industry. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Market Cap
$12.78B
Beta
0.70
P/E (TTM)
79.70
P/E (Fwd)
52.98
EPS (TTM)
$4.07
EPS (Fwd)
$6.12
ROE
11.4%
ROA
6.4%
Cash
$658.8M
Total Debt
$212.7M
Free CF
$161.1M
52W Change
30.8%
Annual Financials
Cash vs Debt
Where PEN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PEN finished 0.18% below its 150-day moving average ($323.00) and 1.44% below its 200-day moving average ($327.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PEN overbought or oversold?
At the October 20, 2026 close, PEN's RSI(14) was 65.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $658.8M in cash comfortably exceeding the $212.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $161.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 11.4%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $847.1M (2022) to $1.40B (2025), reflecting a 66% increase over the period.
With cash comfortably exceeding debt, PEN has financial flexibility that may help navigate uncertain periods. At over 50x earnings, PEN carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing PEN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.